389 related articles for article (PubMed ID: 18256322)
1. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Larson RA; Druker BJ; Guilhot F; O'Brien SG; Riviere GJ; Krahnke T; Gathmann I; Wang Y;
Blood; 2008 Apr; 111(8):4022-8. PubMed ID: 18256322
[TBL] [Abstract][Full Text] [Related]
2. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Guilhot F; Hughes TP; Cortes J; Druker BJ; Baccarani M; Gathmann I; Hayes M; Granvil C; Wang Y
Haematologica; 2012 May; 97(5):731-8. PubMed ID: 22315495
[TBL] [Abstract][Full Text] [Related]
3. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
[TBL] [Abstract][Full Text] [Related]
4. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC.
Koren-Michowitz M; Volchek Y; Naparstek E; Gavish I; Levi I; Rowe JM; Shimoni A; Nagler A
Hematol Oncol; 2012 Dec; 30(4):200-5. PubMed ID: 22241698
[TBL] [Abstract][Full Text] [Related]
5. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
[TBL] [Abstract][Full Text] [Related]
6. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Acta Haematol; 2012; 127(4):221-7. PubMed ID: 22473087
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
9. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
10. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
11. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
[TBL] [Abstract][Full Text] [Related]
12. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Hochhaus A; Druker B; Sawyers C; Guilhot F; Schiffer CA; Cortes J; Niederwieser DW; Gambacorti-Passerini C; Stone RM; Goldman J; Fischer T; O'Brien SG; Reiffers JJ; Mone M; Krahnke T; Talpaz M; Kantarjian HM
Blood; 2008 Feb; 111(3):1039-43. PubMed ID: 17932248
[TBL] [Abstract][Full Text] [Related]
13. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Jabbour E; Kantarjian H; Ghanem H; O'Brien S; Quintas-Cardama A; Garcia-Manero G; Cardenas M; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):302-6. PubMed ID: 23318257
[TBL] [Abstract][Full Text] [Related]
14. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S
Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
18. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.
Kawaguchi T; Hamada A; Hirayama C; Nakashima R; Nambu T; Yamakawa Y; Watanabe H; Horikawa K; Mitsuya H; Saito H
Int J Hematol; 2009 Jun; 89(5):642-8. PubMed ID: 19396513
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
20. Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
Sharma SK; Kumar S; Vijayakumar AR; Seth T; Mishra P; Mahapatra M; Sazawal S; Velpandian T; Saxena R
J Cancer Res Ther; 2014; 10(2):305-8. PubMed ID: 25022382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
